Open AccessRole of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis
Author(s) -
Jochems Caroline,
Islander Ulrika,
Kallkopf Anna,
Lagerquist Marie,
Ohlsson Claes,
Carlsten Hans
Publication year - 2007
Publication title -
arthritis & rheumatism
Language(s) - English
Resource type - Journals
eISSN - 1529-0131
pISSN - 0004-3591
DOI - 10.1002/art.22873
Subject(s) - raloxifene , medicine , selective estrogen receptor modulator , osteoporosis , arthritis , endocrinology , rankl , rheumatoid arthritis , estrogen , estrogen receptor , receptor , cancer , breast cancer , activator (genetics)
Objective In postmenopausal rheumatoid arthritis (RA), both estrogen deficiency and the inflammatory disease contribute to the development of generalized osteoporosis. Hormone replacement therapy (HRT) with estradiol preserves bone mineral density (BMD) and ameliorates arthritis, but long‐term therapy is no longer an option due to significant side effects. We therefore used a mouse model of human RA to test the hypothesis that a selective estrogen receptor modulator (SERM), the raloxifene analog LY117018, could be beneficial in the treatment of both arthritis and osteoporosis. Methods Female DBA/1 mice were ovariectomized and arthritis was induced with collagen immunization. Mice received an injection of raloxifene, estradiol, or vehicle control, administered prophylactically or therapeutically, and thereafter the clinical arthritis score was evaluated continuously. At termination, BMD was analyzed with peripheral quantitative computed tomography. Paws were collected for histology, and sera were analyzed for cytokines and markers of bone and cartilage turnover. Levels of cytokine messenger RNA (mRNA) were investigated with real‐time polymerase chain reaction. Results Treatment with raloxifene dramatically decreased the frequency and severity of arthritis. Effective preservation of bone and cartilage was seen in raloxifene‐exposed mice, as demonstrated by increased BMD and decreased serum levels of cartilage oligomeric matrix protein in the raloxifene‐treated mice compared with controls. Decreased levels of mRNA for both tumor necrosis factor α and RANKL in spleen cells from raloxifene‐treated arthritic mice indicated an immunosuppressive action of this SERM. Conclusion In a well‐established model of postmenopausal RA, the raloxifene analog LY117018 potently inhibits the progression of arthritis and the associated development of osteoporosis, both in a prophylactic and in a therapeutic regimen. Since long‐term HRT has been associated with significant side effects, raloxifene may be a useful adjuvant treatment for postmenopausal RA.